7 terminated. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 7 |
| Phase 2 | 1 | Terminated 1 |
Follow Anemia, Hypochromic: new trials by email Literature Review of Anemia, Hypochromic trials Research Report on Anemia, Hypochromic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iron in Patients With Cardiovascular Disease Ferric carboxymaltose, Saline - Cardiovascular Diseases, Anemia, Iron-deficiency | Phase 3 | Terminated | Dr. med. Mahir Karakas | 8 | 2019-02-28 | 2023-12-27 |
| ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1) Ferric maltol 30 mg (Feraccru®) - Hypertension, Pulmonary, Anemia, Iron Deficiency | Phase 3 | Terminated | Hannover Medical School | 22 | 2018-03-27 | 2020-04-21 |
| A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease Ferumoxytol - Iron Deficiency Anemia | Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 8 | 2011-12-27 | 2022-04-28 |
| A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease Ferumoxytol, Oral Iron - Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease | Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 14 | 2011-10-17 | 2022-04-28 |
| A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease Ferumoxytol, Oral Iron - Iron Deficiency Anemia | Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 14 | 2011-10-17 | 2022-04-04 |
| Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia Ferric carboxymaltose, Ferrous sulfate tablets - Anemia, Iron-Deficiency, Puerperal Disorders | Phase 2 / Phase 3 | Terminated | Norwegian University of Science and Technology | 30 | 2009-06-01 | 2012-02-17 |
| EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure Ferinject ® (Ferric carboxymaltose), Normal saline (0.9%) - Chronic Heart Failure, Iron Deficiency | Phase 3 | Terminated | Vifor Pharma | 35 | 2008-12-01 | 2015-06-03 |
Anemia, Iron-Deficiency (7) · Iron Deficiencies (3) · Anemia (2) · Atrial Fibrillation (1) · Cardiovascular Diseases (1) · Depression, Postpartum (1) · Heart Diseases (1) · Heart Failure, Systolic (1) · Hypertension, Pulmonary (1) · Puerperal Disorders (1) · Renal Insufficiency, Chronic (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Iron Metabolism Disorders (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Anemia (5) · Iron Deficiencies (4) · Cardiovascular Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Arrhythmias, Cardiac (1) · Chronic Disease (1)
Ferrosoferric Oxide (3) · ferric carboxymaltose (3) · Iron (2) · ferrous fumarate (2) · Iron-Dextran Complex (1) · Saline Solution (1) · Sodium Chloride (1) · ferric maltol (1)
AMAG Pharmaceuticals, Inc. (3) · Dr. med. Mahir Karakas (1) · Hannover Medical School (1) · Norwegian University of Science and Technology (1) · Vifor Pharma (1)
Germany (3) · United States (3) · Denmark (1) · France (1) · Israel (1) · Netherlands (1) · Norway (1)
Bjorn Backe, MD PhD (1) · Mahir Karakas, MD, MBA (1) · Marius Hoeper, Prof. Dr. (1) · Michael Motro, MD, FACC (1)
2008 (1)